Finoriq research workspace
Janux Therapeutics, Inc. (JANX) SEC Filings & Filing Highlights
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies. Review JANX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
- Company
- Janux Therapeutics, Inc. (JANX)
- Ticker
- JANX
- Market Cap
- $985.2M
- Latest Price
- $16.16
- Industry
- Biotech & Pharma
Janux Therapeutics, Inc. (JANX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Janux Therapeutics, Inc. (JANX).
| Event | Form | Date |
|---|---|---|
| JANUX THERAPEUTICS, INCOn June 23, 2026, William Go, M.D., Ph.D. departed as Chief Medical Officer of Janux Therapeutics, Inc. (the "Company") under circumstances... | 8-K8.01 | 2026-06-23 |
| On June 11, 2026, Janux Therapeutics, Inc. held the Company’s 2026 Annual Meeting of Stockholde...On June 11, 2026, Janux Therapeutics, Inc. (the “Company”) held the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A... | 8-K5.07 | 2026-06-12 |
| Janux Therapeutics Reports First Quarter 2026 Financial Results and Business HighlightsJanux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights | 8-K2.02 | 2026-05-07 |
| In order to achieve a more equal balance of membership among the three classes of directors on...In order to achieve a more equal balance of membership among the three classes of directors on the Board of Directors (the “Board”) of Janu... | 8-K5.02 | 2026-04-28 |
| Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Hig...Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | 8-K2.02 | 2026-02-26 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.